Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of IND/GLY/MF vs high-dose ICS/LABA for cough in asthma
jRCTs041220003Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma (3 arms), sponsored by Novartis. Primary endpoint: J-LCQ change from baseline at 8 weeks. Started Oct 2022; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on jRCTs041220003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220003.